Interestingly, elevated PPARG (PPAR-γ) expression in BC stromal cells has been reported to be a good positive prognostic marker, associated with longer survival after upfront surgery81, but data reporting a possible effect of PPAR-γ agonist treatment on long-term clinical outcome and LIPEC vessel growth in hormone receptor-positive (ER+, PR+/−)/HER2-negative BC patients are limited. The gene discussed is PPARG; the disease is breast cancer.